دورية
Transcriptional and Metabolic Profiling of Nicotinamide-Enhanced Natural Killer (NAM-NK) Cells (GDA-201)
| العنوان: | Transcriptional and Metabolic Profiling of Nicotinamide-Enhanced Natural Killer (NAM-NK) Cells (GDA-201) |
|---|---|
| المؤلفون: | Yackoubov, Dima, Pato, Aviad, Rifman, Julia, Cohen, Sherri, Hailu, Astar, Persi, Nurit, Berhani-Zipori, Orit, Edri, Avishai, Buhandler, Boaz, Shahor, Moshe, Dinowitz, Nathan, Ben David, Amram, Izraeli, Avi, Caspi, Vered, Levin, Liron, Peled, Amnon, Cichocki, Frank, Rabinowitz, Joshua, Lu, Wenyun, McReynolds, Melanie, Lodie, Tracey, Adams, Julian, Simantov, Ronit, Geffen, Yona |
| المصدر: | Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p4791-4791, 1p |
| مستخلص: | Adoptive transfer of NK cells is a promising immunotherapeutic modality, however limited NK cell persistence and proliferation in vivo have historically been barriers to clinical success. Nicotinamide (NAM), an allosteric inhibitor of NAD-dependent enzymes, has been shown to preserve cell function and prevent differentiation in ex vivo culture of NK (NAM-NK) and other cells. Clinical responses were observed in a Phase 1 trial of NAM-NK (GDA-201) in patients with refractory non-Hodgkin lymphoma (Bachanova, et. al., Blood 134:777, 2019). We now use transcriptional and metabolic profiling to characterize the mechanisms underlying the activity of NAM-NK. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2021-149468 |